Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
RONALD LEVY · STANFORD UNIVERSITY · 2020 · $546,613 — Project Summary: Cancer is a leading global cause of mortality. The goal of this multi-disciplinary project is to pre-clinically advance a novel concept for selective and efficient mRNA delivery that enables a highly promising vaccination strategy for cancer immunotherapy. Given the potential of can…
Brian Geiss · COLORADO STATE UNIVERSITY · 2020 · $374,993 — Approximately 2/3rd of the world population is at risk of infection by at least one of the 35 insect-borne flaviviruses known to cause disease in humans. There are currently few vaccines and no therapeutics available to treat patients infected by flaviviruses such as Dengue, Zika, and West Nile viru…
Barton F. Haynes · DUKE UNIVERSITY · 2020 · $3,798,808 — While HIV-1 broadly neutralizing antibodies (bnAbs) provide potent protection from HIV-1, to date they have been difficult to induce in the setting of vaccination. A second type of HIV-1 envelope (Env) antibodies that are easy to induce are termed non-neutralizing antibodies (NNAbs) (because they ar…
Thomas R Hawn · UNIVERSITY OF WASHINGTON · 2020 · $178,442 — Despite the discovery of Mycobacterium tuberculosis (Mtb) over 100 years ago and the availability of effective drugs for over 60 years, there remain formidable hurdles for controlling tuberculosis (TB) disease including the lack of a highly efficacious vaccine, long drug treatment regimens, preventi…
VICTOR Robert DEFILIPPIS · OREGON HEALTH & SCIENCE UNIVERSITY · 2020 · $640,563 — PROJECT SUMMARY The goals of this R01 proposal include the molecular and immunological characterization of vaccine adjuvant activity associated with processes mediated by the protein Stimulator of Interferon Genes (STING). Two vital insufficiencies are currently evident regarding adjuvanted human va…
DARRICK Albert CARTER · PAI LIFE SCIENCES, INC. · 2020 · $290,045 — PROJECT SUMMARY RNA vaccines are a growing area of interest in vaccinology. They are flexible in that the purification process should be similar from one vaccine to the other and that they can be rapidly made in response to emerging diseases. Use of these nucleic acid constructs as a vaccine platfor…
MARK J SHLOMCHIK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 2020 · $566,843 — Immune memory is critical for pathogen resistance as well as for vaccine efficacy; it is a defining feature of adaptive immunity. To deepen our fundamental understanding of how immune memory works we have fo- cused on elucidating the inherent differences between memory B cells (MBC) and naïve B cell…
Heng Li · DANA-FARBER CANCER INST · 2020 · $423,633 — PROJECT SUMMARY The repertoires of tumor-infiltrating T cells and B cells are rich sources of information about cancer-immune interactions and provide insights on cancer immunotherapy targets. Efforts have been made to characterize B/T cell repertoires in solid tumors using cell sorting followed by …
Zhilong Yang · KANSAS STATE UNIVERSITY · 2020 · $375,906 — Project Summary Although smallpox had been eradicated, the chance the virus could arise from unknown stocks or de novo synthesis remains a credible biothreat. Moreover, other poxviruses cause significant morbidity and mortality in humans and economically important animals; and poxviruses are widely …
Paul Bates · UNIVERSITY OF PENNSYLVANIA · 2020 · $535,986 — Severe Fever with Thrombocytopenia Syndrome virus (SFTSV) is a pathogenic, tick-transmitted bunyavirus that can cause a severe febrile hemorrhagic-like disease with case fatality rates of up to 30%. Discovered during a 2009 outbreak of febrile illness in China, the geographic distribution of SFTSV e…
Gabriel D Victora · ROCKEFELLER UNIVERSITY · 2020 · $454,516 — PROJECT SUMMARY/ABSTRACT Germinal centers (GCs) are site of antibody somatic hypermutation (SHM) and affinity maturation, and are therefore essential for effective humoral immune responses to pathogens. Efficient affinity maturation in GCs requires that B cells cycle between two different cell state…
Sina A Gharib · UNIVERSITY OF WASHINGTON · 2020 · $864,642 — PROJECT SUMMARY Melioidosis, a tropical infection commonly manifesting as acute pneumonia and sepsis in humans, is caused by the Gram-negative Tier 1 select agent Burkholderia pseudomallei and represents a global public health threat with an estimated 165,000 cases and 89,000 deaths annually worldwi…
Koichi Araki · CINCINNATI CHILDRENS HOSP MED CTR · 2020 · $454,637 — CD8 T cells play an important role in controlling viral infections as well as intracellular bacterial and parasitic infections. It is now clear that CD8 T cells are also involved in immunity against tumors and there is considerable interest in cancer immunotherapy that stimulates CD8 T cell response…
Rachel Adria Katzenellenbogen · INDIANA UNIVERSITY INDIANAPOLIS · 2020 · $376,438 — PROJECT SUMMARY/ABSTRACT High-risk human papillomaviruses (HR HPVs) cause 5% of all cancers. There are preventive vaccines against HPV, but less than 2% of the world's target population has received them. This leaves millions of women and men at risk for HPV-associated cervical, anogenital, and hea…
Shinji Makino · UNIVERSITY OF TEXAS MED BR GALVESTON · 2020 · $237,000 — Rift Valley fever Phlebovirus (RVFV), a bunyavirus, belongs to the NIAID Category A list of pathogens and the CDC list of potential bioterrorism agents. RVFV causes a disease that is endemic in sub-Saharan Africa and can emerge in explosive, mosquito-borne epidemics that decimate herds of sheep and …
Jinxiang Zhou · PURILOGICS, LLC · 2020 · $289,381 — Project Summary This SBIR Urgent Competitive Revision will develop the first affinity membrane to purify therapeutic mRNA with high selectivity and throughput. mRNA-based pharmaceuticals have potential to address a wide variety of pathologies. mRNA-based vaccines can increase safety and dramatically…
Zhilong Yang · TEXAS A&M AGRILIFE RESEARCH · 2020 · $378,750 — Project Summary Although smallpox had been eradicated, the chance the virus could arise from unknown stocks or de novo synthesis remains a credible biothreat. Moreover, other poxviruses cause significant morbidity and mortality in humans and economically important animals; and poxviruses are widely …
Sujan Shresta · LA JOLLA INSTITUTE FOR IMMUNOLOGY · 2020 · $761,992 — ABSTRACT The long-term goal of this project is to develop a mRNA replicon-based vaccine that provides long-lived protection against the four serotypes of dengue (DENV1-4) and Zika (ZIKV) viruses. To date, flavivirus vaccine development has focused almost exclusively on the induction of neutralizing …
ALAN REIN · DIVISION OF BASIC SCIENCES - NCI · 2020 · $601,601 — There appear to be several different modes of interaction between retroviral proteins and nucleic acids, each with important functional consequences for viral replication. First, an exquisitely specific recognition by the Gag polyprotein (the structural protein of the virus particle) selects the vir…
Christina Annunziata · DIVISION OF BASIC SCIENCES - NCI · 2020 · $560,328 — Goal 1: Monocytes It has been shown in mouse models of chemically induced cancer that Interferons (IFNs) are important in the immune-surveillance and immune-editing of tumors. While IFNs alpha (IFNa) and gamma (IFNg) have been shown to have potent anti-neoplastic and anti-proliferative properties in…